Welcome to our dedicated page for Sanofi FR SEC filings (Ticker: SNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanofi (SNY) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ and EURONEXT. Sanofi files annual reports on Form 20-F and frequent Form 6-K current reports that incorporate press releases, financial statements, and transaction documents by reference. These filings help investors track Sanofi’s operations as an R&D driven, AI-powered biopharma company focused on medicines and vaccines in immunology, autoimmune disease, rare disease, diabetes, respiratory conditions, and other areas.
Recent 6-K filings referenced in the available data include current reports attaching press releases on product approvals and recommendations (such as Wayrilz for immune thrombocytopenia, Qfitlia and Cablivi approvals in China, and high-dose influenza vaccine data), clinical and regulatory updates for pipeline assets (including tolebrutinib and efdoralprin alfa), and corporate transactions such as the completed acquisition of Vicebio and the planned acquisition of Blueprint Medicines. Other 6-Ks describe debt offerings, including the issuance and pricing of multiple series of fixed and floating rate notes under an indenture, along with the related underwriting agreement and legal opinions.
Sanofi’s interim financial information is also furnished on Form 6-K, including unaudited condensed half-year consolidated financial statements prepared under IFRS. These documents discuss topics such as discontinued operations, joint ventures, contingent consideration, royalties, and financial instruments. Together, the filings provide a detailed view of Sanofi’s capital structure, financing activities, product pipeline progress, and geographic footprint.
On this page, Stock Titan surfaces Sanofi’s latest SEC filings as they are made available from EDGAR and applies AI-powered summaries to help explain the contents of lengthy documents. Users can quickly identify key points in 20-F annual reports, 6-K current reports, and related exhibits, and can review how clinical, regulatory, and financing events are reflected in Sanofi’s official disclosures.
Sanofi furnished a Form 6-K for October 2025, providing an update via an attached press release. Exhibit 99.1 is titled “Q3: continued sales and earnings progress” and is dated October 24, 2025. This filing shares the company’s quarterly narrative through that press release.
The report was signed on October 24, 2025 by Alexandra Roger, Head of Legal Corporate & Finance. Readers can reference Exhibit 99.1 for Sanofi’s Q3 themes around sales and earnings performance.
Sanofi furnished a Form 6-K listing recent company press releases from October 17–20, 2025. The exhibits cover: an EU regulatory review update for Rezurock in chronic graft-vs-host disease; a CHMP recommendation for EU approval of Wayrilz to treat immune thrombocytopenia; new data showing Sanofi’s high-dose influenza vaccine provided superior protection for older adults against hospitalization versus standard-dose; ESMO phase 2 findings for AlphaMedix supporting first-in-class potential in gastroenteropancreatic neuroendocrine tumors; and Tzield being accepted for expedited review in the US through the FDA Commissioner’s National Priority Voucher pilot program.
The filing compiles these updates for investors and incorporates the press releases by reference.
Sanofi furnished a Form 6-K announcing a press release dated October 8, 2025. The release states that AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in a phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This update highlights mid-stage clinical results disclosed via an attached exhibit.
Sanofi reported two corporate developments in an exhibit list attached to its Form 6-K. A press release dated September 23, 2025, states that Sanofi's investigational medicine SAR446268 received U.S. Fast Track designation for the treatment of non-congenital myotonic dystrophy type 1, signaling accelerated regulatory review for that indication. A separate press release dated September 24, 2025, states Sanofi is committing an additional $625 million to Sanofi Ventures to boost investments in biotech and digital health innovation.
Both items are presented as exhibits to the current report and indicate near-term regulatory and strategic investment activity explicitly disclosed by the company.
Sanofi filed a report summarizing two regulatory milestones from September 2025. The company notes a press release on a positive CHMP opinion in the European Union for Dupixent, developed with Regeneron, for treating chronic spontaneous urticaria. A second press release covers an update on the U.S. regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis. The report itself mainly serves to formally furnish these press releases to investors.
Sanofi filed a Form 6-K to share a press release about its experimental medicine amlitelimab. The release states that amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis. This means the treatment achieved the main goals and important additional measures set for this late-stage clinical trial, suggesting a broadly positive result for this patient group.
Sanofi (SNY) filed a Form 6-K that includes an exhibit: a press release dated
The disclosure is concise: it notifies investors that a regulatory approval milestone was achieved for a new therapeutic option in immune thrombocytopenia and that the company has publicly released that information via a press release attached as Exhibit 99.1.
Sanofi filed a Form 6-K reporting an attached press release dated August 14, 2025, announcing that its investigational drug rilzabrutinib received orphan designation in the European Union for the treatment of IgG4-related disease. The filing includes the company signature block signed by Alexandra Roger, Head of Legal Corporate & Finance, dated August 29, 2025. The document is a brief disclosure of the press release and does not contain financial results, transaction details, or additional corporate commentary.
Amundi and Amundi Asset Management report beneficial ownership of 61,769,803 shares of Sanofi (common stock and ADRs), representing 5.03% of the class. The filing shows no sole voting or dispositive power and records shared voting power of 29,534,426 shares and shared dispositive power of 61,769,803 shares.
The filing discloses that 26,790,332 shares are held through an employee FCPE on which Amundi does not exercise voting rights; those voting rights are exercised by the FCPE supervisory board where employee representatives hold the majority. The reporting persons are organized in France and filed this Schedule 13G/A under the Securities Exchange Act.